A retrospective, cohort study assessing the predictive factors associated with outcomes, and optimal duration of therapy of daratumumab in patients with patients with AL amyloidosis
Latest Information Update: 28 Feb 2022
At a glance
- Drugs Daratumumab (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
Most Recent Events
- 28 Feb 2022 New trial record
- 01 Jan 2022 Results published in the American Journal of Hematology